Hemato-oncology
Head Director of Kim Hyun-Soo-
History
History
-
Interview
Interview
-
QA
-
-
Interview
Interview
-
Interview
Interview
The world's first stem cell treatment developer Dr. Hyun-Soo Kim
Head Director of Kim Hyun-Soo Stem Cell Clinic and President of Pharmicell Co., Ltd.
Major Therapeutic Area
- 1. Stem cells: intractable diseases such as myocardial infarction, cirrhosis, spinal cord injury, stroke, erectile dysfunction, or lower limb ischemia.
- 2. Immune cells: Antitumor immune cell therapy
Career
- Head Director of Kim Hyun-Soo Stem Cell Clinic
- President of Pharmicell Co., Ltd.
- Adjunct Professor of at Yonsei University Wonju Severance Christian Hospital
- Director of KITA (Korea International Trade Association)
- Graduated from Ajou University School of Medicine
- Graduated from Yonsei University Wonju College of Medicine
- Former Professor of Department of Molecular Science and Technology, Ajou University
- Former Professor of Department of Biology, Kyonggi University
- Former Professor of Hematology and Oncology, Ajou University
Activity
- Former Member of Self-Regulation Review Committee, Ministry of Food and Drug Safety
- Former Advisor to the Immunological Diseases Council, Ministry of Food and Drug Safety
- Former Member of Planning Committee for Practical Use of Stem Cells, Ministry of Health and Welfare
- Former Member of General Planning Committee for the Synthesis Promotion Plan of Stem Cell Research, and Chairperson of Cell Treatment Division
- Former Member of Bio Industry Strategy Committee, Ministry of Trade, Industry and industry, and Energy
- Former Member of the Korea-US FTA Related Pharmaceutical Industry Development Advisory Committee
- Former Member of the Pharmaceutical Industry Development Council, Ministry of Health and Welfare
- Former Member of Brain Science Area of ULTRA (Universal Linkage for Top Research Advisor) Program, Ministry of Science and ICT
- Former Member of Stem Cell Area of ULTRA (Universal Linkage for Top Research Advisor) Program, Ministry of Science and ICT
- Former Member of Stem Cell Working Committee, Ministry of Science and ICT
- Former Member of the Venture Committee, Korean Tissue Engineering and Engineering, and Regenerative Medicine Society
Award
- Grand Prize in the Health Industry Technology Competition in 2005 (Minister of Health and Welfare)
- Grand Prize in the Industrial Development Category, 5th Korea Health Industry Award in 2011 (Minister of Health and Welfare)
- Listed in one of the three world's major biographical dictionaries (Marquis Who's Who) in 2015
- Selected as a finalist by the 14th Asia Business Leader Award (ABLA) hosted by CNBC in 2015
- Awarded for '2016 Venture Activation' in 2006 (Mister of Trade, Industry, and Energy)
- Albert Nelson Marquis Lifetime Achievement Award in 2017
Patent
- 1. CD8α+ Lymphoid Dendritic Cell Differentiated from Human Hematopoietic Stem Cell and a Method for Differentiation
- 2. Method to Differentiate Mesenchymal Stem Cells into Neurons
- 3. Cosmetic Composition Containing a Liposome in Contact With a Stem Cell Culture Liquid Extract Derived from a Human Body
Stem Cell Therapy
We transfer the blood collected from the patient's bone marrow to a pharmaceutical company (Pharmicell Co., Ltd.) producing a stem cell treatment agent to separate only the mesenchymal stem cells and cultivate them for about four weeks. Doctor will inject the cultured stem cell into specific areas of the patient's veins or diseases that is effective for treatment.
Example of Injecting Stem Cell Treatment Agent by Disease
Coronary Angiography and Injection of Stem Cell Treatment Agent
After placing the tube in the right and left coronary arteries supplying blood to the heart muscle, the radiologic contrast agent is injected selectively into the blood vessel.
Hepatic Angiography and Injection of Stem Cell Treatment Agent
The liver receives oxygen and nutrition through the hepatic artery and portal vein. In patients with cirrhosis, angiography is used to inject a stem cell treatment agent into the hepatic artery to relieve fibrosis of the liver and to improve liver function.
Injection of Stem Cell Treatment Agent into a spinal cord spinal cord or spinal cord
If the spinal cord is damaged, the spinal cord changes. When the tissues are not recovering on its own after the injury, the tissue changes to adipose tissue or remains as an space. We can inject the stem cell treatment agent to the damaged part of the body through the surgery. In the case of spinal cord disease without any changes in the tissues of the spinal cord, it is possible to induce the recovery of the nerve by injecting a stem cell treatment agent into the space between the dermis surrounding the brain and the brain.
Bone Marrow Collection
Bone marrow is an organ with hematopoietic stem cells that make blood and mesenchymal stem cells that can differentiate into tissue. In short, it can be said to be blood in the bone. Usually, the back of the hip bone, the bone area of the spine is stabbed to collect the blood of the bone marrow. It takes about 10 to 20 minutes, and patient suffering is rare.
Total Number of Injected Stem Cell Treatment in 2016-2017: 202 Cases
- Number of Diseases: 7 cases of stroke, 40 cases of central nervous system diseases, 20 cases of spinal cord injury, 18 cases of spinal cord diseases, 16 cases of liver cirrhosis, 6 cases of autoimmune diseases, 10 cases of degenerative arthritis, 21 cases of anti-aging, 51 cases of myocardial infarction, 6 cases of lung disease, 3 cases of impotence and 4 cases of other
- Number of Patients: 156 domestic patients, 46 foreign patients
- Number of Marrow Banking (Storage): 69 cases, as of the end of 2017
Stem Cell Clinic Founded by the Pioneer of Stem Cell Therapy
A role model of a stem cell medical institution that educates doctors about stem cell therapy and gives the right information to the public.
"Despite the ongoing development of stem cell therapies, only a few doctors have experience with proper stem cell therapy. I will show the doctors how to apply the therapy correctly to the patients, and present the role model of the hospital that specializes in stem cell therapy and spread the hope to the patients with incurable disease.” So declared Dr. Hyun-Soo Kim, the developer of world's first stem cell treatment 'Cellgram - AMI, ‘ when he established Kim Hyun-Soo Clinic, a stem cell medical institution. The story of Dr. Hyun-Soo Kim's stem cell treatment development dates back over 20 years ago. As a hematologic tumor specialist, he was a professor at Ajou University hospital. He experienced hematopoietic stem cell transplantation (bone marrow transplantation), which can be called as the origin of stem cell therapy, and directly experienced the therapeutic value of stem cells. As a clinical physician, he has devoted himself to the development of stem cell-based therapies and has raised his skills to a level that can be practically applied to the treatment of diseases.
In 2002, he dropped out of his professorship at the university hospital. He wanted to distribute stem cell therapies to more patients.
He established Pharmicell Co., Ltd. ‘Cellgram-AMI,’. The company’s stem cell medicine was approved as a medicinal product by Korea’s Ministry of Food and Drug Safety in July 2011. Dr. Kim Hyun-Soo won the title of ‘the world's first doctor to develop a stem cell treatment as an approved medicine.’
Since then, four stem cell treatments have been approved by the government authorities in the Republic of Korea. However, there are not many doctors who have used stem cell therapy in the medical field. Even for Dr. Hyun-Soo Kim, a specialist in hematology and oncology who had mainly dealt with bone marrow transplantation, the beginning of stem cells, the time spent on stem cells in medical school education was less than two weeks. It may be natural that the concept of stem cell therapy was unfamiliar to others doctors. Also businesses providing illegal stem cell therapies to even overseas patients, who do not have accurate information about stem cell therapy, appeared in the market.
So Dr. Hyun-Soo Kim opened 'Kim Hyun-Soo Stem Cell Clinic' in Apgujeong-dong, Gangnam-gu, Seoul, to show physicians how to apply the stem cell therapy and provide the public with the right information on stem cell therapy.
Would it be for the conviction and enthusiasm of Dr. Kim, who holds monthly stem cell seminars for specialists every month since he opened his clinic? Physicians who initially suspected of clinical validation of therapeutic efficacy have become convinced of the effectiveness of stem cell therapies after directly experiencing stem cell therapies. The number of cooperating institutions at the national and overseas university hospitals is steadily increasing, and for patients who have difficulty in treatment or need stem cell treatment, the hospitals request medical cooperation from Kim Hyun-Soo Clinic.
The conditions of domestic and foreign patients seeking for the attention of Kim Hyun-Soo Clinic are very diverse, including acute myocardial infarction, cirrhosis, stroke, spinal cord injury, erectile dysfunction, severe ischemia, and cancer patients, many of whom have severe refractory diseases. Stem cell therapy has been able to be safely and effectively treated according to the individual patient's condition, thanks to the vast clinical data accumulated in the past 10 years as a developer of the world's first stem cell therapy drug.
The stubbornness and enthusiasm for which Dr. Hyun-Soo Kim could concentrate only on the stem cells for such a long time was were possible because of his trust in himself and his consciousness as a doctor.
Dr. Hyun-soo Kim stated, "I hope that many refractory patients around the world don’t be despaired in their situation and knock on the door of Kim Hyun-Soo Clinic." "Although stem cell therapy cannot be a panacea, it is certainly the only way to improve the condition of a disease that is impossible to treat with conventional medicine. We will not forget our first intention of giving hope to patients and becoming a medical institution to become a role model for doctors in the medical field,” finally added Dr. Hyun-Soo Kim.
